treatment updates??

just wanna ask poh for any updates for treatments of hep b..

[stef2011]

highest results of hbv eradication by combo of peginterferon+lam for 2 years, entecavir or tenofovir have probably better results because lam is very weak, this combo is used already for some years now

nitazoxanide (alinia) combos lower hbsag and probably help in eradication

interferon lamda has few mild sides, not on the market yet, on hcv trials

[stefen143]

threading for future references:


Ank N et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006 May;80(9):4501-9.

Megjugorac et al. IL-4 enhances IFN-{lambda}1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. Blood, 27 May 2010, Vol. 115, No. 21, pp. 4185-4190

Zhou L et al. Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells. Neuroscience. 2009 Mar 17;159(2):629-37. Epub 2009 Jan 1.

Matsumoto M et al. TLR3: interferon induction by double-stranded RNA including poly(I:C).Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12. Epub 2008 Jan 2.

Yifan Ma et al. Retinoic Acid and Polyriboinosinic:Polyribocytidylic Acid Stimulate Robust Anti-Tetanus Antibody Production while Differentially Regulating Type 1/Type 2 Cytokines and Lymphocyte Populations1. The Journal of Immunology, 2005, 174: 7961-7969.

Nath C et al. Interferon inducer polyriboinosinic-polyribocytidylic acid: a potent anti-gastric ulcer agent and inhibitor of the gastric proton pump in rats. Clinical and experimental pharmacology and physiology. Volume 25, Issue 7-8,  pages 564–567, August 1998

[stefen143]

Toll-like receptor 3 and alpha galactosylceramide:

Schulz O et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005 Feb 24;433(7028):887-92. Epub 2005 Feb 13.

Fujii S et al. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003 Jul 21;198(2):267-79.

Wu CY et al. α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis.Clin Exp Immunol. 2010 Oct;162(1):178-87.

Van Kaer L et al. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol. 2005 Jan;5(1):31-42.

Isogawa M et al. Toll-Like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo. Journal of Virology, June 2005, p. 7269-7272, Vol. 79, No. 11.